Multiple cArdiac seNsors for mAnaGEment of Heart Failure (MANAGE-HF) - Phase I Evaluation of the Integration and Safety of the HeartLogic Multisensor Algorithm in Patients With Heart Failure
Adrian F Hernandez, Nancy M Albert, Larry A Allen, Rezwan Ahmed, Viktoria Averina, John P Boehmer, Martin R Cowie, Christopher V Chien, Marie Galvao, Liviu Klein, Brian Kwan, Carolyn S P Lam, Stephen B Ruble, Craig M Stolen, Kenneth Stein, MANAGE-HF Study, Adrian F Hernandez, Nancy M Albert, Larry A Allen, Rezwan Ahmed, Viktoria Averina, John P Boehmer, Martin R Cowie, Christopher V Chien, Marie Galvao, Liviu Klein, Brian Kwan, Carolyn S P Lam, Stephen B Ruble, Craig M Stolen, Kenneth Stein, MANAGE-HF Study
Abstract
Background: Patients with heart failure (HF) and reduced ejection fraction suffer from a relapsing and remitting disease course, where early treatment changes may improve outcomes. We assessed the clinical integration and safety of the HeartLogic multisensor index and alerts in HF care.
Methods: The Multiple cArdiac seNsors for mAnaGEment of Heart Failure (MANAGE-HF) study enrolled 200 patients with HF and reduced ejection fraction (<35%), New York Heart Association functional class II-III symptoms, implanted with a cardiac resynchronization therapy-defibrillator or and implantable cardioverter defibrillator, who had either a hospitalization for HF within 12 months or unscheduled visit for HF exacerbation within 90 days or an elevated natriuretic peptide concentration (brain natriuretic peptide [BNP] of ≥150 pg/mL or N-terminal pro-BNP [NT-proBNP] of ≥600 pg/mL). This phase included the development of an alert management guide and evaluated changes in medical treatment, natriuretic peptide levels, and safety.
Results: The mean age of participants was 67 years, 68% were men, 81% were White, and 61% had a HF hospitalization in prior 12 months. During follow-up, there were 585 alert cases with an average of 1.76 alert cases per patient-year. HF medications were augmented during 74% of the alert cases. HF treatment augmentation within 2 weeks from an initial alert was associated with more rapid recovery of the HeartLogic Index. Five serious adverse events (0.015 per patient-year) occurred in relation to alert-prompted medication change. NTproBNP levels decreased from median of 1316 pg/mL at baseline to 743 pg/mL at 12 months (P < .001).
Conclusions: HeartLogic alert management was safely implemented in HF care and may optimize HF management. This phase supports further evaluation in larger studies.
Trial registration: ClinicalTrials.gov (NCT03237858).
Keywords: Cardiac devices; decompensation; diagnostics; heart failure; remote monitoring; sensors.
Copyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved.
Source: PubMed